Safety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects - Liu, Yun; Chen, Xiaoning; Tang, Huimin; Jiang, Fan; Tang, Yaqin; Zhu, Huijuan; Du, Yanping; Qian, Hongjie; Liu, Shuyun; Sun, Xiaoshu; Zan, Bin; Zeng, Yuexia; et al. (Clinical and translational science, 2025)
Keywords: a novel pyridone derivative; Administration, Oral; Adult; Adverse events; Antifibrotic Agents - administration & dosage; Antifibrotic Agents - adverse effects; Antifibrotic Agents - pharmacokinetics; Clinical medicine; Delayed-Action Preparations - administration & dosage; Delayed-Action Preparations - adverse effects; Delayed-Action Preparations - pharmacokinetics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Enrollments; exposure–adverse event analysis; Female; Fibrosis; formulation optimization; Half-Life; Healthy Volunteers; Hospitals; Humans; idiopathic pulmonary fibrosis; Idiopathic Pulmonary Fibrosis - drug therapy; Lung diseases; Male; Medical laboratories; Middle Aged; Molecules; Patients; Pharmacokinetics; Pulmonary fibrosis; Pyridones - administration & dosage; Pyridones - adverse effects; Pyridones - pharmacokinetics; Software; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - pharmacokinetics; Young Adult; formulation optimization; idiopathic pulmonary fibrosis; a novel pyridone derivative; exposure–adverse event analysis